Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
Status:
Terminated
Trial end date:
2018-10-10
Target enrollment:
Participant gender:
Summary
The study is designed to assess the safety and efficacy of different doses and dosing
regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in
prevention of liver disease progression in patients with non-alcoholic fatty liver disease
and metabolic syndrome.